JP4914368B2 - Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用 - Google Patents

Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用 Download PDF

Info

Publication number
JP4914368B2
JP4914368B2 JP2007542970A JP2007542970A JP4914368B2 JP 4914368 B2 JP4914368 B2 JP 4914368B2 JP 2007542970 A JP2007542970 A JP 2007542970A JP 2007542970 A JP2007542970 A JP 2007542970A JP 4914368 B2 JP4914368 B2 JP 4914368B2
Authority
JP
Japan
Prior art keywords
gaba
hydroxy
beta
5alpha
3alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007542970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525317A5 (OSRAM
JP2008525317A (ja
Inventor
ベクストルム，トルビエーン
ルンドグレン，ペール
ワン，ミン−デ
Original Assignee
ウメクライン アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウメクライン アーベー filed Critical ウメクライン アーベー
Publication of JP2008525317A publication Critical patent/JP2008525317A/ja
Publication of JP2008525317A5 publication Critical patent/JP2008525317A5/ja
Application granted granted Critical
Publication of JP4914368B2 publication Critical patent/JP4914368B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007542970A 2004-11-18 2005-11-07 Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用 Expired - Fee Related JP4914368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62951104P 2004-11-18 2004-11-18
US60/629,511 2004-11-18
PCT/SE2005/001671 WO2006054938A1 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of cns disorders

Publications (3)

Publication Number Publication Date
JP2008525317A JP2008525317A (ja) 2008-07-17
JP2008525317A5 JP2008525317A5 (OSRAM) 2008-12-25
JP4914368B2 true JP4914368B2 (ja) 2012-04-11

Family

ID=36407411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007542970A Expired - Fee Related JP4914368B2 (ja) 2004-11-18 2005-11-07 Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用

Country Status (11)

Country Link
US (2) US8114860B2 (OSRAM)
EP (1) EP1812009B1 (OSRAM)
JP (1) JP4914368B2 (OSRAM)
CN (1) CN101076340B (OSRAM)
AU (1) AU2005307151B2 (OSRAM)
BR (1) BRPI0518359A2 (OSRAM)
CA (1) CA2585359C (OSRAM)
DK (1) DK1812009T3 (OSRAM)
ES (1) ES2423493T3 (OSRAM)
MX (1) MX2007006032A (OSRAM)
WO (1) WO2006054938A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914368B2 (ja) * 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用
PL2711371T3 (pl) * 2006-11-21 2018-06-29 Asarina Pharma Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
WO2011087441A1 (en) 2010-01-14 2011-07-21 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614499A (en) * 1985-04-29 1986-09-30 Universite Laval Simulator for use as a neurosurgical aid in determining potential paths for the implantation of probes through the human body
ATE307592T1 (de) * 1998-03-11 2005-11-15 Torbjoern Backstroem Epiallopregnanolon zur behandlung von krankheiten des cns
FR2806303B1 (fr) 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
US20030125311A1 (en) * 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
JP4914368B2 (ja) 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用

Also Published As

Publication number Publication date
DK1812009T3 (da) 2013-08-05
US20120142657A1 (en) 2012-06-07
ES2423493T3 (es) 2013-09-20
CN101076340B (zh) 2011-01-12
US20080070876A1 (en) 2008-03-20
EP1812009B1 (en) 2013-05-15
AU2005307151B2 (en) 2011-10-20
US8114860B2 (en) 2012-02-14
JP2008525317A (ja) 2008-07-17
EP1812009A1 (en) 2007-08-01
US8372824B2 (en) 2013-02-12
CN101076340A (zh) 2007-11-21
CA2585359A1 (en) 2006-05-26
BRPI0518359A2 (pt) 2008-11-18
WO2006054938A1 (en) 2006-05-26
MX2007006032A (es) 2007-10-17
EP1812009A4 (en) 2010-08-11
CA2585359C (en) 2013-01-08
AU2005307151A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
JP5006502B2 (ja) ヒトおよび動物におけるコルチゾールおよび他の副腎ホルモンの異常濃度に伴う臨床状態の処置としてのこれらのホルモン濃度の間歇的低下
AU2002242906A1 (en) Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated thereof
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
US11026953B2 (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
JP7179739B2 (ja) 医学的治療における使用のための３－β－ヒドロキシ－５－α－プレグナン－２０－オン

Legal Events

Date Code Title Description
A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20080610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120120

R150 Certificate of patent or registration of utility model

Ref document number: 4914368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees